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Abstract 
 
This paper is concerned with a set of parametric estimators that attempt to provide consistent 
estimates of average medical care costs under conditions of censoring. The main finding is that 
incorporation of the inverse of the probability of an individual not being censored in the estimating 
equations is instrumental in deriving unbiased cost estimates. The success of the approach is 
dependent on the amount of available information on the cost history process. The value of this 
information increases as the degree of censoring increases. 
 
Key words: Cost of medical care; Censoring; Survival analysis; Regression analysis; Health care 
economic evaluation. 
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1. Introduction 
 
The necessity of adopting economic evaluation in the health care sector arises because the market 
fails to fulfil the conditions required to ensure an efficient allocation of resources. Economic 
evaluation provides a method for determining the point of efficiency; that is, the point at which the 
allocation of resources leads to maximisation of social welfare. In the process of achieving the 
optimal resource allocation, alternative states have to be evaluated, each one associated with 
different individual welfare levels. Given that any alternative state of resource allocation will 
normally result in an improvement in welfare for some individuals and a deterioration for others, 
interpersonal comparisons of utility have to be made in order to determine whether there is a net 
gain in social welfare. The choice becomes then either to consider situations in which 
unambiguous welfare improvements are possible or to consider a wider range of situations by 
making interpersonal comparisons. In the former case, evaluation of alternative states is 
undertaken based on the Pareto principle according to which welfare improvement occurs if 
resource allocation is such that an individual is made better off without making another individual 
worse off. In the latter case, value judgements must be made to determine whether there are net 
gains in welfare. In this context, cost-benefit analysis is implemented specifically as a means of 
achieving Pareto welfare. In the health care sector, where the monetary valuation of outcomes is 
complex, cost-effectiveness commonly replaces cost-benefit analysis as a method of identifying 
patterns of health care resource allocation. If relative valuations can be attached to health states, 
then cost-effectiveness may encompass cost-utility analysis. All these methods, cost-benefit, cost-
effectiveness and cost-utility analysis, have specific problems of implementation which have long 
been discussed in the welfare economics literature. Most recently, three particular themes have 
come to dominate the literature in health economics. 
 
First, there has been increasing consideration of the specific technical conditions under which cost-
effectiveness and cost-utility analyses relate to cost-benefit analysis, whose objective is to identify 
Pareto optimal states consistent with the maximisation of social welfare (Garber, 2000; Weinstein 
and Stason, 1976; Weinstein and Zeckhauser, 1973). Secondly, there has been growing criticism of 
the traditional definition of welfare as based on Pareto optimality and utility maximisation 
(Williams and Cookson, 2000; Tsuchiya and Williams, 2001). It has been suggested that the 
definition of welfare ought to take account of concepts that are not solely utility based. The 
justification for this approach derives from Sen’s argument that welfare is not only defined by 
means of utility but is also related to fundamental attributes, which he refers to as ‘basic 
capabilities’ (Sen, 1982). On this basis, proponents of the notion of extra-welfarism have 
suggested that efficiency may be defined with regard to the maximisation of health and not utility 
per se. As such, these capabilities may be related to cardinal measurements of health benefit, 
allowing the problems imposed by interpersonal comparisons to be overcome. Within this context, 
the role of economic evaluation is not to determine the optimal allocation of health care resources 
that will maximise utility-based welfare, but rather to supply the relevant decision makers with 
information that assists their assessment of the appropriate allocation of health care resources. 
Under this interpretation, cost-effectiveness and cost-utility analyses are not necessarily related to 
cost-benefit analysis as there is no attempt to follow Paretian notions of efficiency. Cost-
effectiveness and cost-utility analyses become appropriate allocative tools in their own right. The 
third theme that has dominated the literature has dealt with measurement issues given that any 
economic evaluation involves measurement of the costs incurred by and the benefits derived from 
a health care intervention. Particular emphasis has been given to the measurement of the benefits 
derived from a given health outcome. At the same time, there is a sizeable literature that considers 
the measurement of the relative valuations of health states using non-monetary values (Dolan, 
2000, 2001). A directly related literature considers the relative strengths and weaknesses of the 
various measures. Other measurement-related issues that have received some attention in the 
literature include adjustments for missing data, the measurement of indirect costs and the 
transferability of findings across different regulatory environments. 
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This paper relates to the general aspect of measurement issues. Having focused on measurement 
problems raised within the context of analysing health outcome data, the literature has generally 
given less attention to the issues that arise in the analysis of cost data. With respect to cost, the 
matter most commonly addressed is the definition and measurement of indirect costs (Sculpher, 
2001). The measurement of direct costs has received less attention. There is a relatively small 
literature which considers the appropriate definition of direct costs and their relationship to 
opportunity costs and charges (Brouwer et al, 2001; Dranove, 1996). There is limited 
consideration, however, of the impact that different data collection methods and different 
methodological approaches employed in analysing cost data have on the estimates of cost 
statistics. The limited information available with regard to direct cost measurement in general and 
the lack of a well-established methodology in dealing with particular statistical issues arising in the 
analysis of treatment costs are themselves a justification for the subject matter that follows. 
 
The study of medical care costs presents a number of analytical difficulties. An issue of particular 
concern arises when a specific form of incomplete information is present in the data, a condition 
which is referred to as censoring. An individual whose behaviour with respect to the variable under 
study is not observed for the full duration of interest is said to be censored. Thus patients who are 
lost to follow-up, drop out of the study or are observed until the termination of the study period 
without having reached the event of interest will be right censored.1 Given the bias imparted by 
this loss of information, estimators of statistics of interest must account for the presence of 
censoring in the data. While both parametric and non-parametric approaches have been applied to 
the analysis of time-to-event data, yielding estimators which successfully account for censoring, 
applications where the random variable of interest is cost-to-event have generally placed emphasis 
on non-parametric estimation (Lin et al, 1997; Bang and Tsiatis, 2000).  
 
The primary advantage of non-parametric models is that they are free of assumptions concerning 
the distribution of the variable of interest. There are circumstances, however, where parametric 
methods may be the preferred or necessary alternative. A parametric approach can provide 
information on the pattern of cost accumulation by assessing individual covariate effects on cost or 
by modelling the relationship between cumulative cost and time. As such, parametric models can 
provide an instrument for extrapolating estimates of costs over the study period to different 
populations or to points in time exceeding the duration of the study. Although the usefulness of 
parametric modelling in analysing censored cost data has been acknowledged in the literature and 
there have been a number of approaches introduced recently, their validation has not been explored 
adequately. This paper presents an attempt to address this issue by studying a set of alternative 
parametric estimators of cost under conditions of censoring and by assessing their performance 
empirically under conditions of heavy censoring.  
 
As in the case of non-parametric models (e.g. Fenn et al, 1995), the earliest attempts to account for 
censoring in deriving estimates of mean cost using a parametric approach involved direct 
application of the classical survival techniques to censored cost data. The Cox proportional hazards 
model and the Weibull and exponential models were applied, for example, by Dudley et al (1993) 
and Fenn et al (1996) in studying covariate effects on cumulative cost and in providing mean cost 
estimates over the study period. These approaches, however, generally lead to biased estimates for 
the same reason as their non-parametric counterparts; that is, due to the presence of dependent 
censoring between the variable of interest and its censoring variable (Lin et al, 1997; Etzioni et al, 
1999). As in the non-parametric approach to the analysis of time-to-event data, the central concept 
in the semiparametric and parametric approaches is the conditional probability of an event 
occurring at a given point in time, given that it has not occurred until that point in time as modelled 
through the hazard functions. For all these models, independent censoring requires that individuals 
who are censored at time t (after allowing for covariates) are representative of all individuals who 
                                                 
1
 Another form of censoring, referred to as left censoring, is associated with incomplete information due to 
individuals entering the study at different points of progression to endpoint, but it is relatively uncommon in 
medical studies and is not considered in this paper. 
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are still under observation at t. When applying these approaches to modelling cost-to-event data, 
individuals who are censored having attained a particular cost level must be representative of all 
individuals who are still under observation having attained that cost level. This is not normally the 
case, as patients who are in poorer health states generate higher costs per unit of time and 
consequently are expected to generate higher cumulative costs at both the failure time and the 
censoring time, thus implying positive correlation between cost at failure and cost at censoring. 
Failure of these approaches to account for censoring in the cost estimates has led to two proposed 
alternatives. The first adopts a regression approach where cost is modelled as a function of failure 
time and adjustment for censoring in the cost estimates is achieved through adjusting failure time 
for censoring. The second uses a linear regression approach where cost is related to a set of 
individual covariates and adjustment for censoring in the cost estimates is performed by using the 
inverse of the probability of an individual not being censored in the estimating equations. These 
estimators of cost together with their properties and underlying assumptions are considered below.  
 
Assessment of the estimators’ performance is achieved through direct comparison of the resultant 
parametric estimates to their non-parametric counterparts derived from the application of a set of 
previously studied (non-parametric) estimators, using the same dataset as presented in Raikou and 
McGuire (2004). This allows exploration of whether the estimators’ asymptotic properties are 
maintained in a practical setting. The paper proceeds as follows. The general setting for the 
analysis is outlined first and the set of parametric estimators for cost together with the assumptions 
underlying their validity are then presented. The resultant cost estimates derived from the 
application of the alternative regression methodologies to a medical dataset which exhibits heavy 
censoring follow. Some concluding remarks and suggestions are then given. 
 
 
2. Analytical framework  
 
2.1. General setting  
 
The basic aim of the approaches presented below is to derive an estimate of the mean total cost 
)(ME=µ and its variance over a specified period when the data is right censored, where the 
random variable M denotes the total cost for a patient during some specified time T and E denotes 
expectation. The distribution of the random variable T is assumed continuous over ] ,0( L , where L 
denotes the upper bound of T and M is the total cost incurred by a patient up to a maximum of L 
units of time. To accommodate censoring, a potential time to censoring denoted by U is defined 
and letting T denote time to death, the observables from a study in the presence of censoring are 
),min( UTX = , i.e. the last contact date; )( UTI ≤=δ , where )(⋅I  is the indicator function 
taking the value of 1 when the argument is true (i.e. if the observation is uncensored) and zero 
otherwise; the cost accrued up to time X and other intermediate cost history for each subject, i.e. 
{ }tuuMtM H ≤=  ,)()( , where )(tM H  denotes the cost history up to time t, )(TMM = , with 
)(uM  being the known accumulated cost up to time u and u denoting points in time at which cost 
information becomes available. Letting )',...,( 1 pZZZ =  denote a 1×p  vector of the covariates 
of interest, the observable data for n individuals are then the independent and identically 
distributed random vectors { } niZXMUTIUTX iiHiiiiiii ,...,1 , ),(   ,)(   ,),min( =≤== δ , where i identifies an individual. 
 
2.2. Least squares regression analysis with randomly right-censored data 
 
Assuming the general setting as defined above and defining ) ,min( LTT =∗ , with Z  being a 
1×p  vector of covariates whose effect on the cumulative cost at ∗T  one wishes to study, the 
methodology presented in this section introduced by Lin (2000) attempts to adjust the estimates 
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derived by the linear model given as εβ +′= ZM , where β  is a 1×p  vector of unknown 
regression parameters and ε  is a zero-mean error term with an unspecified distribution for 
censoring. The first term of Z is set equal to 1 so that the first term of β  corresponds to the 
intercept. In the absence of censoring, β  is estimated by the least-squares normal equation 
 
∑
=
=−
n
i
iii ZZM
1
' 0)( β  
 
In the presence of censoring, estimation by the above equation will lead to biased estimates for the 
regression parameters (Lancaster, 1990; Green, 1997). A naïve approach is to estimate the model 
by including only the uncensored cases in the estimation process. The regression parameters are 
again estimated by the least-squares normal equation but now only individuals with complete cost 
observations contribute information to the estimation process. As is the case in any similar missing 
data situation, such an analysis, referred to as complete case analysis, which totally discards the 
cases with missing values, leads to loss of information which could be a substantial problem if the 
proportion of cases with missing values is high. On this basis, the approach has been deemed 
useful only for providing a baseline method for comparisons. In contrast, the approach proposed 
by Lin (2000) accounts for the presence of censoring as follows. Under the assumption of a 
continuous distribution for failure time over ] ,0( L  and a continuous distribution of censoring time 
with censoring arising in a completely random manner, time to censoring has the survivor function 
)()( uUpruK >= , i.e. the survivor function )(uK evaluated at a point in time u gives the 
probability of an individual not being censored at u. Defining )( ∗∗ ≥= TUIiδ  under random 
censoring conditions, the estimating equation for β  is modified as: 
0)()(1 *
=′−∑
=
∗n
i
iii
i
i ZZM
TK
βδ   
 
which implies that only individuals with complete cost observations over the duration of interest 
contribute cost information to the estimation process. The unknown survivor function )(⋅K  is 
estimated by the Kaplan-Meier estimator (Kaplan and Meier, 1958) based on the data 
{ }niUTX iiii ,...,1 ,1 ),,min( =−= δ  as ∏
≤ 





−=
tu
c
uY
udN
tK )(
)(1)(ˆ , where ∑
=
=
n
i
c
i
c uNuN
1
)()(  
counts the number of individuals censored over time with )0,()( =≤= iici uXIuN δ  and 
∑
=
=
n
i
i uYuY
1
)()(  counts the number of individuals at risk over time with )()( uXIuY ii ≥= . 
Replacing the survivor function )(⋅K  with its consistent Kaplan-Meier estimator results in the 
following estimating equation for β :  
 
0)(
)(ˆ1 *
=′−∑
=
∗n
i
iii
i
i ZZM
TK
βδ  , whose solution is given as 
 
∑∑
=
∗
∗
−
=
⊗
∗
∗








=
n
i
ii
i
i
n
i
i
i
i ZM
TK
Z
TK 1
1
1
2
)(ˆ)(ˆ
ˆ
δδβ  , where αααααα ′=== ⊗⊗⊗ 210  , ,1 . 
 
Thus the main idea underlying this approach is to weight the uncensored observations by the 
inverse of the probability of an individual not being censored evaluated at the time of the 
individual’s failure. The idea underlying the use of this specific weight is that under conditions of 
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independent censoring, at time iT , )()( ii TUprTK >=  is the probability that individual i has 
survived to iT  without being censored. Therefore any individual who is observed to die at iT  
represents on average )(/1 iTK  individuals who might have been observed if there was no 
censoring. The same idea underlies the approach by Koul et al (1981) within the context of failure 
time regression analysis when the dependent variable (time to event) is subject to censoring. Lin 
(2000) studies the asymptotic properties of this estimator and derives estimates for its covariance 
matrix for large samples using the martingale version of the central limit theorem. The mean cost 
over ] ,0( L  can then be estimated as ZM ~ˆˆ β ′= , where Z~  denotes the covariates vector evaluated 
at the mean values of the covariates.  
 
 
2.3. Least squares regression analysis with randomly right-censored data: multiple time 
intervals 
 
The second approach presented by Lin (2000) extends the previous idea in situations where 
information on individual cost histories is available at various points in time over the duration of 
interest. The main purpose of this method is to increase efficiency by allowing use of cost 
information not being used by the preceding estimator. Adopting the same framework as Liang et 
al (1986), Lin (2000) models the marginal expectation of cost at each point in time for which cost 
information is available as a function of the covariates as follows. The duration of analysis ] ,0( L  
is partitioned into K subintervals ),...,1( ,] ,( 1 Kktt kk =− , with 00 =t  and LtK = , and for each 
subinterval k the following linear model is assumed: 
 
kiikki ZM εβ +′=  Kk ,...,1=  ni ,...,1=  
where for individual i, )()( 1−−= kikiik tMtMM  is the cost incurred over subinterval ] ,( 1 kk tt − , 
),...,1( Kkk =β  are 1×p  vectors of unknown regression parameters and the error terms s'kiε are 
assumed to be independent among different subjects but allowed to be correlated within the same 
subject. By summing over all k subintervals, the linear model for the cost over the whole duration 
of interest becomes iii ZM εβ +′=  ni ,...,1= , where ∑
=
=
K
k
kii MM
1
, ∑
=
=
K
k
k
1
ββ , and 
∑
=
=
K
k
kii
1
εε . Defining ) ,min( kiki tTT =∗  and )( ∗∗ ≥= kiiki TUIδ , i.e. { }ikiki UtTI ≤=∗ ),min(δ , 
the estimating equation for ),...,1( Kkk =β  is given as 0)()(ˆ1 * =′−∑=
∗n
i
iikki
ki
ki ZZM
TK
βδ , where 
)(ˆ ∗kiTK  is the Kaplan-Meier estimator for the probability of not being censored based on the 
dataset { }niX kiki ,...,1, , =∗δ , where ),min( ikiki UTX ∗= . The solution to the above estimating 
equation is then given as: 
iki
n
i ki
ki
n
i
i
ki
ki
k ZMTK
Z
TK ∑∑ = ∗
∗
−
=
⊗
∗
∗








=
1
1
1
2
)(ˆ)(ˆ
ˆ
δδβ  with 
∑ ∑∑
= =
∗
∗
−
=
⊗
∗
∗
















=
K
k
n
i
iki
ki
ki
n
i
i
ki
ki ZM
TK
Z
TK1 1
1
1
2
)(ˆ)(ˆ
ˆ
δδβ . 
 
Comparing this estimator with its counterpart from the previous approach, the gain in cost 
information is due to the fact that here a subject contributes cost information to the estimating 
 9 
equations over all time intervals for which the individual is not censored, i.e. over all ks for which 
),min( * kii tTU > . By contrast, in the previous estimator an individual only contributes cost 
information to the estimates if the individual has reached the event of interest or the individual’s 
censoring time exceeds the maximum observed time in the study. In studying the asymptotic 
properties of this estimator, the same methodology as for the previous estimator is adopted and a 
consistent estimator for the covariance matrix is derived. The mean cost over ] ,0( L  can be 
estimated as ZM ~ˆˆ β ′= , where Z~  denotes the covariates vector evaluated at the mean values of 
the covariates.2  
 
 
2.4. Two-stage regression 
 
Carides et al (2000) proposed an estimator for mean cost in which the total cumulative cost is 
modelled as a function of failure time. Their method was introduced as an attempt to overcome the 
limitation of the Lin et al (1997) non-parametric approach associated with the requirement of a 
discrete censoring pattern to ensure the estimator’s consistency. Their estimator is referred to as a 
two-stage estimator because at the first stage of the estimation process the expected cost at any 
given point in time is estimated as a function of failure time and at the second stage the estimated 
expected costs at given points in time are weighted by the Kaplan–Meier probability of death at 
these points in time. The estimate of mean total cost is derived as the sum over time of these 
weighted individual cost estimates. Under this model the mean cost is therefore given by: 
 
∫
∞
=
0
)()( tdStgµ   
where )()( tTMEtg ==  is the expected cost of an individual with survival time T and 
)()( tTprtS ≥= . The first stage involves deriving an estimator )(ˆ tg  for )()( tTMEtg ==  
using a regression approach. The authors suggest that the regression be performed only on the 
uncensored observations on the basis that the treatment costs of censored individuals typically 
differ from the treatment costs of uncensored individuals at the same point in time and inclusion of 
censored observations will therefore impart bias into the estimate of )(tg . The second stage of the 
estimation process involves the weighting of the estimated regression function )(ˆ tg  by the 
Kaplan-Meier estimate of the probability of death at time t. The two-stage estimator of the mean 
cost over ] ,0( L  is then given as ∫=
L
TS tSdtg
0
)(ˆ)(ˆµˆ  
where )(ˆ tg  is an estimator for )()( tTMEtg ==  and )(ˆ tS  is the Kaplan-Meier estimator for 
)()( tTprtS ≥= , that is, ∏
≤ 




 ∆
−=
ts sY
sN
tS )(
)(1)(ˆ , where ∑
=
=
n
i
i sNsN
1
)()(  counts the number 
of individuals dying over time with )1,()( =≤= iii sXIsN δ  and )(sY  counts the number of 
                                                 
2
 Both approaches described above are generalised to the case of covariate-dependent censoring. To 
accommodate covariate dependent censoring, Lin (2000) proposes using the proportional hazards 
specification (Cox, 1972) to model the effect of covariates on the censoring distribution allowing 
formulation of the dependence of censoring both on discrete covariates, which might be used as stratification 
variables, and on continuous covariates. The asymptotic properties for both these estimators and the 
expressions for the limiting covariance matrices reported by Lin (2000) are derived adopting the same 
analytical framework as for the case of covariate independent censoring and follow as a direct generalisation 
of the results presented above for the covariate independent censoring case. In addition, the methods are not 
restricted by the censoring pattern or by the number of covariates. 
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individuals at risk over time as defined above3. The choice of the functional form for )(tg  
depends mainly on the data under consideration and the authors suggest use of either a parametric 
regression model or a non-parametric smoother. In the case of a parametric regression, the authors 
consider models which are, with or without some transformation of the data, linear in the 
coefficients, thus allowing use of the ordinary least squares regression technique to derive 
estimates for the regression parameters.4 
Due to the consistency of the Kaplan-Meier estimator, consistency of the two-stage estimator is 
ensured if the parametric model )(tg  is consistently estimated. Although under specific 
parametric assumptions the two-stage estimator is asymptotically normal with variance estimator 
directly following from the specific statistical distribution, the authors recommend that for 
practical purposes the bootstrap method be used to derive standard error estimates for the mean, as 
they argue that the assumption of asymptotic normality is unlikely to be valid in most applications. 
The authors conclude that such a regression based approach, where the relationship between cost 
and failure time is specified through a parametric model, is advantageous compared to a non-
parametric approach due to efficiency gains resulting from the use of such a relationship. On the 
other hand, this is only going to be the case if the parameterisation reflects the true functional form 
of cost and failure time. In the event of model misspecification, a non-parametric approach for 
estimating the relationship between cost and failure time will be preferred.  
 
 
                                                 
3
 If the last observed time corresponds to censoring in which case the Kaplan-Meier estimator is undefined 
(Kaplan and Meier, 1958), to ensure consistency the estimator can be expressed as 
)(ˆ)(ˆ)(ˆˆ
0
LSMtSdtg Lu
L
TS ≥+= ∫µ  where LuM ≥  is an estimate of cost accumulated over ] ,0( L  for patients who 
survive beyond L. 
 
4
 The models considered in this analysis follow the authors’ suggestions and are specified as: 
1. Linear relationship between total costs and failure time as iii TM εββ ++= 10 , where the error terms are 
normally distributed with zero mean and finite variance, so that the two-stage estimator for mean cost is 
tM µββ ˆˆˆˆ 10 += , where 0ˆβ  and 1ˆβ  are estimated from ordinary least squares regression using only the 
uncensored cost observations and ∫=
t
t duuS
0
)(ˆµˆ  is the Kaplan-Meier estimator for mean survival time over 
] ,0( t . 
2. Linear relationship between costs transformed on the natural logarithm scale and failure time as 
iii TM εββ ++= 10ln , where the error term has a lognormal distribution. The mean cost is teM µββ ˆ
ˆˆ
10ˆ +
= , 
where 0ˆβ  and 1ˆβ  are the estimates from the ordinary least squares regression using the uncensored 
observations only and 
tµˆ  is the Kaplan-Meier estimate for mean survival time. Given that the error 
distribution in the untransformed scale is unknown, Duan (1983) suggested using a non-parametric estimator 
for the untransformed scale expectation referred to as the smearing estimator. The estimate for the mean cost 
incorporating Duan’s smearing estimator is ∑
=
+
=
n
i
it e
n
eM
1
ˆˆ
ˆˆ 1
ˆ 10 εµββ , where 0ˆβ  and 1ˆβ  are the estimates from 
the ordinary least squares regression on the uncensored observations only, 
tµˆ  is the Kaplan-Meier estimate 
for mean survival time and iεˆ  are the ordinary least squares residuals.  
3. Linear relationship between costs transformed on the natural logarithm scale once more and failure time 
as iii TM εββ ++= ln)ln(ln 10 . The mean cost without smearing is teeM µββ ˆ1
ˆ0ˆ
ˆ
+
=  and with smearing is 
∑
=
+
=
n
i
ee it
e
n
M
1
ˆ)ˆ1ˆ0ˆ(1
ˆ
εµββ
, where 0ˆβ  and 1ˆβ  are the estimates from the ordinary least squares regression using 
the uncensored observations only, 
tµˆ  is the Kaplan-Meier estimate for mean survival time and iεˆ  are the 
ordinary least squares residuals.  
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3. Methods and results 
 
3.1. Methods 
 
The parametric estimators defined above were applied to a medical dataset which exhibited 
extreme levels of censoring. The data were taken from a randomised controlled clinical trial and 
relate to a type 2 diabetic population of 3867 individuals allocated either to conventional policy 
(1138) or intensive policy (2729) with the aim of assessing the effectiveness of improved blood 
glucose control over a median follow-up period to death, the last date at which clinical status was 
known, or to the end of the trial period of 10 years. For each individual in the study, information 
on both clinical effectiveness and resource use was collected within the trial. Unit costs of resource 
use were attached to the recorded volume of resources to calculate the total cost per patient per 
year directly from the trial data and these were then aggregated to give a total cost per patient for 
the whole trial period. The analysis in this paper aims at deriving an estimate of average total cost 
over the trial period adjusting for censoring where an observation was defined as censored if the 
patient was not observed for the full time to death. Thus the failure event was all-cause mortality, 
resulting in 925 censored patients [81.3% censoring] and 213 failures in the conventional group 
and 2240 censored patients [82% censoring] and 489 failures in the intensive group by the end of 
the trial. Average follow-up time was equal to 9.9 years reaching a maximum of 18.93 years for 
the conventional group and 10.01 years reaching a maximum of 19.46 years for the intensive 
group. Despite the long duration of the trial, loss to follow-up and drop-out rates were negligible. 
The levels of censoring arising in the trial largely reflect the low mortality rates in both arms at the 
termination of the study. The assumption of independent censoring is valid in these data as 
censoring was not related to any cost or medical reasons. 
 
All estimators were applied to these trial data within each randomisation group, where for each 
individual the observables were time to death or last contact, a variable taking the values of 0 or 1 
indicating censoring or failure respectively, the annual costs and the total cost from the start of 
follow-up to death or the last contact date and a set of time independent covariates that represented 
measurements obtained on each individual at the start of the study on age, body mass index (bmi), 
fasting plasma glucose level (fpg), race and sex. The descriptive statistics for each of the 
covariates are shown in Table 1. As can be seen from Table 1, there are no differences in the 
baseline covariate values between the two groups. These covariates were deemed clinically 
meaningful given that fasting plasma glucose level provides the means of defining diabetes and 
body mass index gives an indication of obesity which is highly positively correlated with the risk 
of diabetes as is age. There is also evidence of racial differences in the incidence and prevalence of 
diabetes with, for example, higher rates in the Asian population. The fact that these covariates 
were deemed important explanatory variables for diabetes progression and complications does not 
imply that they will necessarily explain cost, especially as they were only measured at the start of 
the study. However, this represents the most frequent pattern of covariate measurements within a 
clinical trial setting, where interest lies in recording disease-specific predictive factors at the time 
of the individual’s entry to the study and in certain cases at various points in time over the follow-
up period. 
 12 
 
Table 1. Baseline covariate values in conventional and intensive policy groups 
 
Mean 
Standard 
deviation Minimum Maximum 
Conventional (n=1138)     
Age (years) 53.40 8.69 25.62 72 
Bmi (kg/m2) 27.80 5.46 17.57 55.68 
Fpg (mmol/l) 8.48 2.03 5.5 17.5 
Race 1.32 0.72 1 5 
Sex 1.38 0.49 1 2 
Intensive (n=2729)     
Age (years) 53.21 8.62 24.69 72 
Bmi (kg/m2) 27.49 5.07 16.59 60.61 
Fpg (mmol/l) 8.61 2.14 5.4 19.9 
Race 1.31 0.70 1 5 
Sex 1.39 0.49 1 2 
 
With respect to the methodology proposed by Carides et al (2000), the estimates of mean survival 
time used in all parameterisations were 15.65 years (se=0.21) for the conventional policy group 
and 15.96 years (se=0.18) for the intensive policy group. The analysis undertaken here derived 
mean estimates with and without smearing. An indication of the underlying relationship between 
treatment cost and study time is given in Figure 1 which plots the observed costs against time for 
the censored and uncensored populations for both trial arms. 
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Figure 1. Total cost per patient over the study period for conventional and intensive policy groups 
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The regression methodology proposed by Lin (2000) was applied to the data both when individual 
costs were available at the last contact date or death (failure time) and when multiple observations 
at different points in time were available for each individual. In the second model, annual time 
intervals were assumed for each individual because intermediate cost history was available for 
each subject on an annual basis. The classical linear regression model was estimated using the 
uncensored cases only as a baseline means for comparison to the alternative linear regression 
methodologies. All regression models aside from those proposed by Carides et al, which used 
failure time as the independent variable, were based on the set of covariates described above. 
Estimates of the variance associated with the mean estimators resulting from the above models 
were derived using the bootstrap approach with the estimates being obtained from 1000 
replications. The reason for using the bootstrap approach is that the asymptotic variance estimators 
for the mean cost have not been defined. For compatibility purposes, estimates of the regression 
parameter standard errors for the Lin regression models as well as for the naïve ordinary least 
squares regression were also derived using the bootstrap approach.   
 
3.2. Results 
 
The results derived from the parametric approaches are shown in Table 3, while Table 2 reports 
the best non-parametric estimates obtained from a previous study by Raikou and McGuire (2004) 
as a means of assessing the parametric estimators’ performance. Based on the conclusions drawn 
in this earlier study, two non-parametric estimators of within study average cost, one proposed by 
Lin et al (1997) and one proposed by Bang and Tsiatis (2000), both of which make use of 
information on intermediate cost histories, were deemed to perform adequately across a wide range 
of censoring levels. Given that these two estimators remained stable even under the extreme 
censoring conditions arising in the trial data, it can be confidently asserted that the resultant cost 
estimates reflect the true cost values.
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Table 2. Best non-parametric estimators of mean cost 
 
Conventional Intensive 
Estimator Mean Standard error Mean Standard error 
Lin1 (Lin et al 1997) ( 1ˆ LINµ ) 14006.2 897.73 13172 340.55 
Bang and Tsiatis Partitioned ( Pµˆ ) 14639.48 1219.4 13839.67 445.6 
 
 
 
Table 3. Parametric estimators of mean cost 
 Conventional Intensive 
Estimator Mean Standard error Mean Standard error 
Carides et al regression models     
total cost on time 20353.71 2551.99 19548.07 1228.00 
ln(total cost) on time without 
smearing 
18086.73 2599.06 21096 1927.38  
ln(total cost) on time with 
smearing 
16070.78 1914.10 17939.50 1368.74  
ln(ln(total cost)) on time without 
smearing 
19080.38 3155.30 23132.24 2680.18  
ln(ln(total cost) on time with 
smearing 
18959.67 3152.28  21626.47 2545.91 
Lin regression methodology     
Complete costs  14015.82 3588.94 17573.79 1961.70  
Multiple intervals 14941.14 1274.07 13789.33 452.70  
Naïve OLS  11708.78 1268.10 10845.21 693.58 
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With respect to the Carides et al two-stage estimator, the resultant mean cost estimates are high 
relative to the non-parametric estimates for both groups.5 Moreover, the difference in average cost 
between the treatment arms is generally of the wrong expected direction given that the expected 
direction of difference in the average cost between the two trial arms is that the conventional group 
has higher average treatment costs than the intensive group, largely due to a higher hospitalisation 
rate. Although the approach is appealing as it attempts to model the time pattern of cost and is not 
restricted by assumptions concerning the censoring distribution, the analysis reveals the 
estimator’s inadequate performance under all the parameterisations considered. This finding holds 
even when smearing estimates were obtained following a logarithmic transformation to account for 
positive skewness in the cost data. While model misspecification is liable to be a contributory 
factor, the estimator’s inadequate performance is more likely attributed to the high degree of 
censoring present in the data. As the regression parameters are estimated using information from 
the uncensored cases alone, which in this case amounts to a mere 18% of the total number of 
observations and will reflect the bias imparted from a complete case analysis, it is to be expected 
that the estimated coefficients will not reflect the true parameter values, even assuming that the 
relationship between cost and failure time is correctly specified. 
 
This postulate is supported further by the results obtained when the expected costs were estimated 
by a non-parametric regression approach. Carides et al (2000) recommend use of such a regression 
when there is not enough confidence in a specific parametric relationship between cost and 
survival time. The method adopted provides smoothed estimates of cost using locally weighted 
scatterplot smoothing (lowess) according to which the smoothed values of the dependent variable 
are derived by running a regression of the dependent variable on the independent variable using for 
each estimate the data at the estimation point and a small amount of data near the point. In lowess 
the regression is weighted so that the central point each time receives the highest weight and points 
farther away receive less. A separate weighted regression is estimated for each point in the data in 
order to provide the smoothed estimates. Applying this approach resulted in estimates of mean cost 
of 5674.92 (se=853.24) for the conventional group and 9407.87 (se= 3230.63) for the intensive 
group where the standard errors were obtained from 1000 bootstrap replications. Such an approach 
for deriving expected cost estimates, being free of assumptions about the functional form between 
cost and failure time, gives a strong indication that an equally important, if not more important, 
source of bias aside from model misspecification in the Carides et al estimator is the high level of 
censoring. This was to be expected based on the results obtained from the non-parametric 
estimators which only used cost information from the complete cases as presented in Raikou and 
McGuire (2004). Both the respective Lin et al (1997) and Bang and Tsiatis (2000) non-parametric 
estimators performed inadequately when only complete costs were included in the estimation 
process and both techniques showed dramatic improvement when information was increased by 
incorporating individual cost histories into the estimating equations. 
 
Before considering the set of parametric estimators proposed by Lin (2000), the estimates derived 
from the naïve ordinary least squares regression are discussed.6 The estimates derived from this 
approach are known to be biased as they are based on a complete-case analysis which ignores all 
censored observations, but as stated above, they provide a means for baseline comparisons to the 
alternative linear regression methodologies and in particular to Lin’s (2000) regression models, 
which are a direct extension of this approach and use the same set of covariates. Although the 
naïve least squares regression resulted in the expected direction of the difference between the two 
arms of the trial, with the conventional group incurring higher costs on average than the intensive, 
the estimates of mean cost are low for both groups. This was anticipated as the information from 
censored observations is not used in the estimation process and it is known that the bias increases 
as the level of censoring increases. Comparison of the ordinary least squares cost estimates with 
the non-parametric uncensored cases estimates reported in Raikou and McGuire (2004) – which 
were 11901.01 (se=1061.36) and 10629.97 (se=510.00) for the conventional and intensive arms 
                                                 
5
 Estimated regression coefficients for the various models available on request. 
6
 Estimated regression coefficients available on request. 
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respectively – reveals a close similarity which confirms that ordinary least squares regression 
results in biased estimates when the outcome variable is censored.  
 
With respect to Lin’s (2000) parametric approach that uses information only on the complete total 
costs, the resultant difference in mean cost between the trial arms is of the wrong expected 
direction. In addition, the estimated mean cost for the intensive group is much higher than 
expected. This pattern alters when the regression uses information on multiple cost observations on 
each patient obtained at a number of points in time over the study period. The latter approach 
results in estimates that are very close to its non-parametric counterparts, derived from the first Lin 
non-parametric method using information on individual cost histories, and even closer to the Bang 
and Tsiatis partitioned estimator, which again uses information on individual cost histories. Thus, 
the regression model which uses cost history information from all individuals results in a 
significant improvement compared to the parametric model which discards cost information from 
the censored cases. This was anticipated and confirms Lin’s argument that the multiple time 
intervals approach improves efficiency by using information that is ignored by the complete costs 
approach. The estimates of the regression parameters for both Lin regression models and the naïve 
ordinary least squares regression are reported in Table 4. 
 
Table 4. Estimated regression parameters for the naïve OLS and the Lin regression models 
 Conventional Intensive 
Estimator Regression 
coefficients 
Standard error  Regression 
coefficients 
Standard 
error  
Naïve OLS     
Const -23980.37  13813.83    5647.46    8007.90    
Age  262.47    161.68    57.55    100.61    
Bmi 454.01    258.15    34.84    108.39     
fpg  537.43    654.39    -176.55 231.98    
Race 1783.51    1990.84    146.71    998.54    
Sex 1545.94    2627.59    1802.75    1318.99    
Lin complete costs     
Const -21043.55 25522.02 32901.42 24882.84 
Age  141.61 337.58 -211.60 315.09 
Bmi 596.27 610.46 208.61 267.38 
fpg  1099.66 1012.11 -979.99 753.35    
Race 1424.06 4309.11 1740.02 2739.86    
Sex -206.40 8907.59 -2619.76 4142.53    
Lin multiple intervals      
Const -217.49 8723.92 12170.94* 4883.95 
Age  -16.99 141.88 1.86 41.83    
Bmi 127.08 211.20    23.84 108.31    
fpg  1493.37* 634.84  148.15 187.03    
Race -247.16 1711.94    -863.83 630.64    
Sex 139.01 3271.34    517.88 806.28     
*
significant at the 5% level 
 
The coefficient estimates resulting from all these regressions indicate that the covariates have low 
explanatory power, although it should be emphasised that high standard errors on individual 
coefficients cannot be taken to mean that any particular model in its entirety has low predictive 
power. With respect to the individual coefficients in the Lin regression models, all are insignificant 
in the complete costs approach and significant only for fasting plasma glucose in the conventional 
group in the multiple time intervals approach. This finding is not surprising given that the set of 
available covariates has been determined by their clinical rather than economic importance. Of 
greater importance is the finding that the mean cost estimates derived from the multiple time 
intervals regression model appear much improved, being very close to the comparative non-
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parametric estimates, relative to the respective cost estimates resulting from the complete costs 
regression. As both regressions use the same inverse probability weight in an attempt to account 
for censoring, the most likely explanation for this result is the increased cost information used in 
conjunction with the particular weight by the multiple intervals regression. In an attempt to explore 
the sensitivity of the mean cost estimates to the set of covariates included in the models, both Lin 
estimators were applied to the data incorporating fasting plasma glucose as the only covariate. The 
results together with the naïve ordinary least squares estimates are shown in Table 5 for the 
regression parameters and in Table 6 for the mean costs. 
 
Table 5. Estimated regression parameters using fasting plasma glucose as the only covariate 
 Conventional Intensive 
Estimator Regression 
coefficients  
Standard error  Regression 
coefficients  
Standard error  
Naïve OLS     
Const 7367.78    5391.06    12142.42*  2171.18     
fpg  602.40    624.86    -144.15 232.21    
Lin complete costs     
Const -466.98 9367.33 24497.55* 8912.96     
fpg  1690.44 968.63    -891.05 996.83    
Lin multiple intervals     
Const 4263.38 3963.33    13220.31* 1948.28     
fpg  1270.71* 575.85 99.13 203.60    
*
significant at the 5% level 
 
Table 6. Estimated mean costs from regression models using fasting plasma glucose as the 
only covariate 
 Conventional Intensive 
Estimator Mean Standard error Mean Standard error 
Lin complete costs  13870.84 7060.85 16821.34 2419.14 
Lin multiple intervals 15041.21 1578.42 14074.33 454.88 
Naïve OLS 12477.19 1212.05 10900.58 560.30 
 
The mean cost estimates resulting from the regressions in which fasting plasma glucose was the 
sole covariate are very similar to their respective counterparts derived from the models using the 
complete set of covariates. In this particular application, therefore, the choice of the set of 
covariates does not appear to have an impact on the resultant mean cost estimates. The inverse of 
the probability of an individual not being censored entering the estimating equations seems to be 
primarily responsible for the resultant predicted mean estimates. However, this particular weight 
alone is incapable of adequately adjusting for the loss of information when the level of censoring is 
too high as indicated by the poor performance of the complete costs regression. As was the case in 
the non-parametric analysis (Raikou and McGuire, 2004), the amount of available information on 
the cost history process proves as important as the probability weight, which adjusts the estimates 
for the information loss due to censoring.  
 
 
4. Concluding comments 
 
Parametric approaches provide a necessary alternative in deriving estimates of cost statistics in a 
number of circumstances, such as when interest lies in the assessment of individual covariate 
effects on cost or in the extrapolation of estimates beyond the observed study duration or to 
different patient populations. Inherent in all parametric approaches is the specification of a 
functional form for the relationship between the outcome variable and a set of independent 
variables. Naturally, a first candidate in this category would be the classical linear regression 
model with cost forming the dependent variable, but such an approach is known to yield biased 
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estimates when the outcome variable is drawn from a censored distribution. The naïve solution of 
estimating the regression parameters by completely discarding the censored cases from the 
estimation process is also biased, with the degree of bias increasing as the proportion of censored 
observations increases. This, together with the failure of parametric and semiparametric regression 
models traditionally used in the analysis of time to event data to account for censoring in the cost 
estimates due to dependent censoring between cost at event and cost at censoring, has led to a set 
of alternative regression methodologies within the context of parametric censored cost analysis.  
 
The first of these methodologies, introduced by Carides et al (2000), adopts a regression approach 
where cost is modelled as a function of failure time and adjustment for censoring in the cost 
estimates is achieved through adjusting failure time for censoring. Consistency of the estimator is 
ensured if the regression model specifying the relationship between cost and failure time is 
consistently estimated. The second alternative, introduced by Lin (2000), uses a linear regression 
approach where cost is related to a set of individual covariates and adjustment for censoring in the 
cost estimates is performed through use of the inverse of the probability of an individual not being 
censored in the estimating equations. The method has been shown theoretically to derive consistent 
estimates of the regression parameters while accounting for the presence of censoring and is not 
restricted by the censoring pattern. Two estimators result from this approach. The first uses the 
individual total accumulated costs at the individual’s point of failure or end of study, while the 
second makes use of multiple cost observations obtained on each subject at various points in time 
over the study period. The main advantage of the latter estimator is an increase in efficiency by 
allowing use of cost information that is not used by the preceding estimator.  
 
Although the estimators’ statistical properties have been studied theoretically, their performance 
under conditions of heavy censoring has not been assessed empirically. This issue is addressed in 
this study through applying the proposed estimators to a clinical dataset that exhibits high levels of 
censoring and comparing the resultant estimates with the respective estimates derived from the 
best non-parametric estimators previously applied to the same data (Raikou and McGuire, 2004). 
The main findings are as follows. The Carides et al estimator resulted in biased estimates for all 
parameterisations considered for the relationship between cost and failure time. The results 
suggested that the major source of bias was the high degree of censoring rather than a potential 
misspecification of the regression model as similar results were obtained under a number of 
alternative parameterisations for the relationship between cost and failure time. Given that under 
this approach bias in the cost estimates arises from bias in the estimates of the regression 
parameters, it is not surprising that the estimated coefficients do not reflect the true parameter 
values when their derivation was based on only 18% of the observed data which constituted the 
uncensored subset. Therefore, although such an approach is appealing on the basis that it attempts 
to model the time pattern of cost, it is of limited value at high levels of censoring. Given the 
potential value of methods that allow extrapolation of cost beyond the study period, development 
of parametric models that successfully do so under conditions of heavy censoring appears to be a 
fruitful area for future research. Concentrating on the Lin regression methodology, the approach 
using cost information solely from the complete cases yielded biased estimates of cost as expected 
given the limited amount of cost information entering the estimation process, while the approach 
using information on individual cost histories resulted in estimates that were very close to the ones 
derived from the best performing non-parametric methods, which also use information on the 
individual cost history process.  
 
These findings provide further insight into the general issue of cost estimation in the presence of 
censoring in the following manner. Aside from identifying a regression methodology which 
performs well under extreme censoring conditions, the results of this analysis strengthen the 
validity of the main conclusion reached in the corresponding non-parametric analysis reported 
previously. The general finding emerging from this analysis is that incorporation of the inverse of 
the probability of an individual not being censored in the estimating equations is instrumental in 
deriving unbiased estimates of medical care costs under conditions of censoring. Nevertheless, the 
success of the approach is dependent on the amount of available information on the cost history 
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process, as this will in turn determine the degree of retrieval of cost information missing due to 
censoring. In circumstances where the level of censoring is high, knowledge of the history of the 
process under study proves a determining factor in the performance of the estimator. The 
implication for the design of a clinical study where data on medical resource use are collected is 
that effort should be made to record information on cost generating events on each individual at 
intermediate points in time over the study duration. The findings derived from the preceding 
analysis provide conclusive evidence in support of this requirement, with the value of the available 
information on the cost history process increasing as the degree of censoring increases.  
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